anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There are over 1,719 United States (US) state and federal prisons with over 2.3 million prisoners. In 2017, more than 20% of sentenced prisoners were age 50 or older. The health status of older inmates is often parallel with free-living people who are far older (e.g., 10-15 years). Older prisoners disproportionately contribute to the steeply rising correctional healthcare costs and their death rate is 10 times that of younger prisoners. Corrections budgets are stretched as they strive to meet the care needs of aged and dying prisoners. Carefully selected and vetted inmates offer an abundant human resource that is poised to contribute in important ways to augment prison staff in meeting growing care needs of older and dying inmates. However, the lack of standardized, evidence-based, training that is geared toward this target audience is a current barrier to ensuring high quality inmate caregiving. In response to this need, our Phase I project E-training of Inmate Peer Caregivers for Enhancing Geriatric and End-of-Life Care in Prisons demonstrated that inmate access to technology is growing and inmates can be successful e-learners. Specifically, we learned: (1) there is a need and interest for products such as our Inmates Care computer-based learning (CBL); (2) trainings should be engaging, interactive, and contextually sensitive to the specific environment, target user, and security constraints, while at the same time being mindful of emerging trends in regard to technology use by inmates (e.g., availability of tablets for purchase and use in many states); and finally, (3) that interactive, media-rich prototype modules with high acceptability and usability could be developed. The specifications document and commercialization plan indicated it is possible to develop a full-scale Inmates Care learning system in Phase II and a Technology Niche Analyses® revealed market potential exists. The purpose of this Phase II application is to continue research and development of the Inmates Care learning system with an emphasis on developing a scalable unit for commercialization and testing scale-up in a larger number of more diverse state prisons. More specifically, the aims of this Phase II study are to: 1) Develop a full scale media-rich interactive computer-based learning system Inmates Care, that consists of six modules aimed at augmenting the highly variable face-to-face inmate caregiving programs in state prisons with standardized, evidence-based training to prepare inmates in assisting with end-of-life (EOL) and geriatric care; and one Training Overview and Rollout module that prepares staff to use Inmates Care as a tool for inmate peer caregiver training; 2) Conduct in-person usability testing of the full-scale Inmates Care program in two rounds in state prisons to evaluate logistics, inmate and staff impressions, user interface, ease of use, and perceived barriers in order to optimize the scalable unit for broader dissemination (n=30); and 3) Test scale-up of the full-scale Inmates Care program in state prisons across the nation to evaluate knowledge acquisition outcomes, usage patterns, and commercialization opportunities (n=288).
We aimed to determine the role of cathepsin S (CTSS) in modulating oxidative stress-induced immune and inflammatory reactions and angiogenesis in age-related macular degeneration. Human retinal pigment epithelium cells line ARPE-19 (immature) were maintained and treated with H2O2. The expression of CTSS, inflammatory cytokines, and complement factors induced by oxidative stress was compared between cells incubated without (control) and with CTSS knockdown (using small interfering ribonucleic acid; siRNA). To evaluate the role of CTSS in angiogenesis, we assayed tube formation using human umbilical vein endothelial cells and conditioned medium from ARPE-19 cells. We also used a mouse model of laser-induced choroidal neovascularization. CTSS levels were higher in ARPE-19 cells treated with H2O2 than in control cells. Oxidative stress-induced CTSS resulted in significantly elevated transcription of nuclear factor kappa B-dependent inflammatory cytokines, complement factors C3a and C5a, membrane attack complex (C5b-9), and C3a and C5a receptors. siRNA-mediated knockdown of CTSS reduced the number of inflammatory signals. Furthermore, oxidative stress-induced CTSS regulated the expression of peroxisome proliferator-activated receptor γ and vascular endothelial growth factor A/Akt serine/threonine kinase family signaling, which led to angiogenesis. Tube formation assays and mouse models of choroidal neovascularization revealed that CTSS knockdown ameliorated angiogenesis in vitro and in vivo. The present findings suggest that CTSS modulates the complement pathway, inflammatory reactions, and neovascularization, and that CTSS knockdown induces potent immunomodulatory effects. Hence, it could be a promising target for the prevention and treatment of early- and late-stage age-related macular degeneration.
The present invention relates to kidney nourishing medicinal wine which belongs to the technical field of a traditional Chinese drug. Presenility, premature ejaculation, impotence, exhaustion, weakness, etc. which are caused by renal deficiency and menoxenia, dysmenorrhea, leukorrhea, etc. which are caused by Qi and blood deficiency and stasis symptoms are common diseases of the same class. The present invention aims to provide medicinal wine which can effectively and quickly enhance human body immunity and eliminate various ailments which can be caused by renal deficiency, Qi and blood deficiency and stasis symptoms and a manufacture method thereof. The medicinal wine is manufactured by soaking traditional Chinese drugs of glossy privet fruit, dodder, wolfberry fruit, schisandrae, broomrape, dog kidneys, white atractylodes rhizome, pseudostellaria roots, raw astragalus roots, antlers, sea horses, prepared rhizome of rehmannia, etc. into spirit, yellow wine or grape wine at room temperature for at least 20 days, and 2 to 30g of each of the traditional Chinese drugs is added into 1000 ml of wine.
This randomized clinical trial will be conducted in Autism center Lahore. Sample of 76 patients will be recruited in this trial by using the convenience sampling technique. Participants will be randomly allocated in two groups using lottery method. Group A will receive Rhythmic balance visual auditory exercise. Group B will receive strength training exercises. Both groups will receive routine physical therapy as baseline treatment. All the participants will receive 3 sessions per week for 12 weeks.Bruininks-Oseretsky Test of Motor Proficiency (BOT-2) will be used assessment tool to measure fine and gross motor skills and Wisconsin Card Sorting Test (WCST) will be assessment tool that evaluates cognitive flexibility and problem-solving abilities.
Patients with EGFR-mutant NSCLC would receive bevacizumab plus first-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Erlotinib 150 mg tablets once daily or Gefitinib 250mg once daily or Icotinib 125mg three times a day would be administered.
PURPOSE: To provide a pharmaceutical and food composition that is very effective as a remedy for a cold and a preventive for pollinosis with high safety by allowing a powder comprising plant seeds of citrus family and plant fruits of euphorbia family to absorb concentrated infusion of the plant roots of lily family and Theaceae family. CONSTITUTION: Seeds of a citrus plant [for example, citron (Citrus junos)] and fruits of an euphorbia plant (for example, Phyllanthus emblica) are combined, ground, dried and crushed to prepare the main flour. The roots of plants in lily family, for example, golden-banded lily (Lilium auratum Lindl) or day lily (Hemerocallis fulva) and the roots of plants of Theaceae family, for example, Camellia oleifera Abel are cut into fine pieces, thoroughly infused with water, gradually concentrated by evaporation, the concentrate is roughly filtered, allowed to stand for cooling for a while. Then, the concentrated infusion is absorbed in the above-stated main flour and dried. Finally, crushing and sieving are repeated to prepare fine powder of uniform particle size.  In a preferred embodiment, citrus seeds and Phyllanthus fruits are used in amounts of 15-25 pts.wt., respectively and the roots of lily and Theaceae family, in amounts of 25-30 pts.wt., respectively.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine and is intended for improvement of gum quality before elimination of gum recession in patients with periodontal inflammatory diseases. Punctures in zone of keratinised gum are performed on perimeter and more apically than gum recession by means of needle No 27G - 30G with piercing-cutting tip. Needle is introduced subepithelially into layer of own mucous membrane, where, without bringing needle out, 3-5 microcuts are made for formation of microhematomas in proper mucous layer of fixed gum. Depth of cutting plane location is not less than 0.3-0.5 mm. Length of each microcut constitutes 1-1.5 mm at 2 mm distance from each other. 2 times per day on area of flap preparation applied is composition of the following formulation: preparation "Vetoron"- 10%, base - siliconorganic glycerohydrogel with formulation: Si(C3H7O3)46C3H8O324H2O(AB-I-50) - 90%. Microcuts are performed three times with 7-10 day interval, during entire tome of flap preparation. Said composition is applied on dry gum surface twice a day for 10 minutes. ^ EFFECT: method makes it possible to increase gum thickness for preparation for surgical treatment. ^ 3 ex
Patients and their caregivers must be instructed that Lazanda contains medicine in an amount that could be fatal to a child.

Patients and their caregivers must be instructed to keep both used and unused bottles in their child-resistant container and out of the reach of children at all times. Partially used bottles represent a special risk to children. As soon as they are no longer required, all used, unopened or partially used bottles must be completely emptied of accessible fentanyl solution by spraying the remaining contents into the carbon-lined pouch. The sealed pouch and the empty bottle should be put into the child-resistant container before discarding in the trash. Hands must be washed with soap and water immediately after handling the pouch. [see Storage and Handling (16.2), Disposal of Lazanda (16.3), and Patient/Caregiver Instructions (17.1)].

Physicians and dispensing pharmacists must question patients and caregivers specifically about the presence of children in the home on a full-time or visiting basis and counsel accordingly regarding the dangers to children of inadvertent exposure to Lazanda.

Lazanda could be fatal to individuals for whom it is not prescribed and for those who are not opioid tolerant.
A system to diagnose respiratory disease(s) in real-time is provided. The system includes a data receiving subsystem which receives multiple radiogram images and annotation(s) of a lung area. The system also includes a radiogram-image processing subsystem which extracts a boundary of the lung area and compares with the annotation(s) of the lung area and then generates notification(s) upon detection of a mismatch between the boundary of the lung area and the annotation(s) of the lung area. Further, the system includes a diagnostic subsystem which extracts multiple features from the lung area. The multiple features include at least one of entropy, a homogeneity, a standard deviation of average intensity, a bronchi angle, a tracheal shift, or a combination thereof of the lung area. The diagnostic subsystem also analyzes the multiple features and generates a diagnosis report for the patient(s) to diagnose the respiratory disease(s) in real-time.
BACKGROUND: Liver ischaemia/reperfusion (I/R) injury, which is an inevitable clinical problem of liver resection, liver transplantation and haemorrhagic shock. Fibroblast growth factor 21 (FGF21) was intimately coupled with multiple metabolic processes and proved to protect against apoptosis and inflammatory response in hepatocytes during hepatic I/R injury. However, the regulatory mechanisms of FGF21 in hepatic I/R injury remains unknown. Therefore, we hypothesize that FGF21 protects hepatic tissues from I/R injury.
METHODS: Blood samples were available from haemangiomas patients undergoing hepatectomy and murine liver I/R model and used to further evaluate the serum levels of FGF21 both in humans and mice. We further explored the regulatory mechanisms of FGF21 in murine liver I/R model by using FGF21-knockout mice (FGF21-KO mice) and FGF21-overexpression transgenic mice (FGF21-OE mice) fed a high-fat or ketogenic diet.
RESULTS: Our results show that the circulating levels of FGF21 were robustly decreased after liver I/R in both humans and mice. Silencing FGF21 expression with FGF21-KO mice aggravates liver injury at 6 h after 75 min of partial liver ischaemia, while FGF21-OE mice display alleviated hepatic I/R injury and inflammatory response. Compared with chow diet mice, exogenous FGF21 decreases the levels of aminotransferase, histological changes, apoptosis and inflammatory response in hepatic I/R injury treatment mice with a high-fat diet. Meanwhile, ketogenic diet mice are not sensitive to hepatic I/R injury.
CONCLUSIONS: The circulating contents of FGF21 are decreased during liver warm I/R injury and exogenous FGF21 exerts hepatoprotective effects on hepatic I/R injury. Thus, FGF21 regulates hepatic I/R injury and may be a key therapeutic target.
Currently, there is no approved medical treatment for preservation of the body's ability to produce insulin in patients with Type 1 Diabetes Mellitus (T1DM), and the progression of the disease can have devastating consequences. Inadequate blood glucose control results in many long term complications including kidney disease, blindness, amputation and nerve damage. In spite of the advances in insulin therapy and subsequent glucose control, patients are required to infuse insulin subcutaneously daily throughout their lives, monitor their diet and blood sugar levels, and deal with life-long uncertainties. The investigational therapy under study in this trial, regulatory T cells (Tregs), offers the hope of stabilizing diabetes. Tregs are a specialized subset of T cells that function to control the immune response. Pre-clinical studies in non-obese diabetic mice have demonstrated that adoptive transfer of Tregs can slow diabetes progression and, in some cases, reverse new onset diabetes. The primary objective of this study is to assess the safety of a single intravenous infusion of Tregs in patients with T1DM. The study will also assess the effect of Tregs on insulin-producing beta cell function as well as other outcomes related to diabetes management. Researchers will isolate Tregs from the patient's own blood using specific T cell surface markers (CD4, CD25, and CD127). This subset of cells is then expanded in the laboratory by co-stimulating with anti-CD3 and anti-CD28 immobilized on magnetic beads, and with the use of growth medium containing human serum and IL-2. Following the 14-day expansion, anti-CD3/anti-CD28 beads will be removed and the Tregs will be concentrated and consolidated. The cells will then be resuspended in sterile infusion solution at the required concentration and infused back into the patient through a standard peripheral intravenous line. Subjects will be observed overnight in the clinical research center for any possible side effects following the infusion. A total of 14 subjects will be enrolled. The study will involve 4 dosing cohorts with 3 or 4 adults in each cohort. Each cohort will receive increasing amounts of Tregs. Subjects will be followed over five years to assess safety of the Treg therapy.
Eligible patients will be included and treated with docetaxel intravenously (75mg/m2)in every three weeks cycles and LDE225 will be administered orally at three dose levels 400, 600 and 800mg QD. Treatment will be repeated on day 1 of a 21-day cycle until radiographic or symptomatic progression, unacceptable toxicity or withdraws informed consent.
BACKGROUND AND OBJECTIVE: In this work, the analysis of the importance of hemodynamic updates on a mechanobiological model of atheroma plaque formation is proposed.
METHODS: For that, we use an idealized and axisymmetric model of carotid artery. In addition, the behavior of endothelial cells depending on hemodynamical changes is analyzed too. A total of three computational simulations are carried out and their results are compared: an uncoupled model and two models that consider the opposite behavior of endothelial cells caused by hemodynamic changes. The model considers transient blood flow using the Navier-Stokes equation. Plasma flow across the endothelium is determined with Darcy's law and the Kedem-Katchalsky equations, considering the three-pore model, which is also employed for the flow of substances across the endothelium. The behavior of the considered substances in the arterial wall is modeled with convection-diffusion-reaction equations, and the arterial wall is modeled as a hyperelastic Yeoh's material.
RESULTS: Significant variations are noted in both the morphology and stenosis ratio of the plaques when comparing the uncoupled model to the two models incorporating updates for geometry and hemodynamic stimuli. Besides, the phenomenon of double-stenosis is naturally reproduced in the models that consider both geometric and hemodynamical changes due to plaque growth, whereas it cannot be predicted in the uncoupled model.
CONCLUSIONS: The findings indicate that integrating the plaque growth model with geometric and hemodynamic settings is essential in determining the ultimate shape and dimensions of the carotid plaque.
PROBLEM TO BE SOLVED: To obtain a new compound useful as a preventive/therapeutic agent for nephropathy. SOLUTION: This new compound (salt) is expressed by formula I (R<1> is a 5- or 6-membered heteroaromatic cycle containing one O or S atom with the ring substitutable with lower alkyl (s), 6-membered heteroaromatic cycle containing one N atom; A is an alkylene or polymethylene; R<2> is H, a lower alkyl or acyl; R<3> is H, a metal atom or lower alkyl), e.g. 2-hydroxy-4-(2- thenylthio)butanoic acid. The compound of formula I is obtained by reaction between a compound of the formula R<1> -L (L is an eliminatble group) and 2- hydroxy-4-mercaptobutanoic acid of formula II in a solvent (e.g. ethanol) at 0 deg.C to the boiling point of the solvent.  This compound is useful for treating nephrotic syndrome, diabetic nephropathy and cataract resulted therefrom, nephropathy due to hyperuricemia, nephropathy due to gouty nephropathy, nephropathy due to acute renal failure, nephropathy induced by medicinals or heavy metals. A medicinal composition containing 0.1-99.5wt.% of the compound of formula I as active ingredient is prepared, its dose being 0.5-3000mg/ day.
Potential patients will be referred to coordinating centers by their healthcare provider (treating physician, diagnosing physician or primary care physician) and if eligible will be invited to enroll in the registry. The Registry Coordinating Center will be responsible for obtaining consent from adult patients and caregivers of minor patients (as well as assent from minors when appropriate), screening patients and enrolling them in the registry.

The registry will capture data entered by the patient, the patient's healthcare provider, and the patient's caregiver using online (electronic) survey tools administered at baseline, and annually thereafter. The patient's healthcare provider will complete the baseline Healthcare Provider survey tool, reporting the patient's baseline demographics, medical history, clinical information, and disease characteristics. The patient and caregiver will complete their dedicated baseline survey tools answering questions on the impact of disease on their everyday life. Survey tools include questions on patient and caregiver demographics, patient physical activity, patient food and hunger episodes, patient quality of life, and caregiver's perspective of disease burden on the family. Registry patients, caregivers, and healthcare providers will be contacted annually (approximately every 12 months) by the Registry Coordinating Center to complete an online follow-up survey tool including a smaller subset of questions from the baseline survey tools.
The present invention refers to aerosol formulations for administering drugs, more particularly, salbutamol by inhalation. The invention provides novel aerosol formulations comprising (a) Salbutamol, (b) a polar co-solvent and (c) a hydrofluorocarbon (HFC) or hydrofluoroalkane (HFA) propellant. The formulation is characterized in that it is chlorofluorocarbon (CFC) propellant-free, containing the drug completely solubilized therein, which facilitates the absorption of the active principle by the airways; the invention ensures the uniformity of the doses administered in each shot and promotes the physical stability of the final formulation. The invention is further characterized in that the salbutamol is drug-free and the formula is contained in a suitable aluminium container, which does not have any inner coating. The present invention includes a non-conventional manufacturing method useful for dispensing the components of the formula without requiring freezing or especial environment al conditions, the same being practically, quickly and easily operated as especial cooling fittings are not required, the dispensing action can be adjusted during the process. Said method is more cost effective since an additional energy consumption is not required, and has the same advantages of the conventional filling method under cooling.
The present invention relates to traditional Chinese medicine preparation for treating coronary disease and angina pectoris, and a production method for the traditional Chinese medicine preparation. The present invention belongs to the technical field of traditional Chinese medicine preparation and a preparation method. The present invention aims at solving a technical problem of providing traditional Chinese medicine preparation and a production method thereof, wherein the traditional Chinese medicine preparation eliminates unsuitable smell and has rapid effects and improved therapeutic effects; the traditional Chinese medicine preparation is composed of the following raw material medicine and extracts of the raw material medicine: the clathrate of beta-CD red sage root and of the volatile oil of chuanxiong rhizome, dried objects of alcohol depositing and water boiling extracts of red sage root, chuanxiong rhizome, astragalus root and red peony root, the clathrate of beta-CD borneol, and notoginseng. The production method comprises: extracting and covering the volatile oil of the chuanxiong rhizomes and the red sage roots; preparing the alcohol depositing and water boiling extracts of the red sage root, the chuanxiong rhizome, the astragalus root and the red peony root; covering the borneol; producing powder; mixing and matching. The production method of the present invention can extract the effective components in the raw material medicine to a larger extent, and solves the problem of volatilization loss at a normal temperature during production and storage. The medicine of the traditional Chinese medicine preparation has rapid effects, and has no unsuitable smell The present invention has good therapeutic effects.